ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

被引：0
|
作者：
Sandborn, William J.
Vermeire, Severine
Peyrin-Biroulet, Laurent
Dubinsky, Marla C.
Panes, Julian
Yarur, Andres J.
Ritter, Timothy E.
Baert, Filip J.
Sloan, Sheldon
Cataldi, Fabio
Shan, Kevin
Rabbat, Christopher J.
Chiorean, Michael V.
Wolf, Douglas C.
Sands, Bruce E.
D'Haens, Geert
Danese, Silvio
Goetsch, Martina
Feagan, Brian G.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
968a
引用
收藏
页码：S1395 / S1395
页数：1
相关论文
共 50 条
  • [11] Efficacy and safety of etrasimod in patients with moderately to severely active UC in Japan: Integrated analysis of the phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN trials
    Takeuchi, K.
    Hisamatsu, T.
    Nakase, H.
    Matsuoka, K.
    Keating, M.
    Yuasa, H.
    Oe, M.
    Arai, S.
    Hibi, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I644 - I645
  • [12] Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials
    Takeuchi, Ken
    Hisamatsu, Tadakazu
    Nakase, Hiroshi
    Matsuoka, Katsuyoshi
    Keating, Michael
    Yuasa, Hirotoshi
    Oe, Motoki
    Arai, Shoko
    Mazur, Rafal
    Hibi, Toshifumi
    DIGESTION, 2024,
  • [13] Efficacy and Safety of Etrasimod in Patients With and Without Concomitant Corticosteroid Treatment in the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
    Sands, Bruce E.
    Gecse, Krisztina B.
    Rubin, David T.
    Leung, Yvette
    Panes, Julian
    Goetsch, Martina
    Wang, Wenjin
    Shan, Kevin
    Woolcott, John C.
    Smith, Christina C.
    Wosik, Karolina
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S808 - S809
  • [14] Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
    Siegmund, B.
    Ryan, R.
    Abreu, M. T.
    Vermeire, S.
    Dotan, I.
    Goetsch, M.
    Crosby, C.
    Woolcott, J.
    Komori, H. K.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 700 - 700
  • [15] CHARACTERIZATION OF PLASMA INFLAMMATORY PROTEIN ABUNDANCE IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH ETRASIMOD: AN EXPLORATORY ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
    Siegmund, Britta
    Ryan, Rathi D.
    Abreu, Maria T.
    Vermeire, Severine
    Dotan, Iris
    Goetsch, Martina
    Crosby, Catherine
    Woolcott, John
    Komori, H. Kiyomi
    Danese, Silvio
    GASTROENTEROLOGY, 2023, 164 (06) : S659 - S659
  • [16] Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
    Lees, C.
    Torres, J.
    Leung, Y.
    Vermeire, S.
    Fellmann, M.
    Modesto, I.
    McDonnell, A.
    Lazin, K.
    Keating, M.
    Goetsch, M.
    Wu, J.
    Loftus, E. V., Jr.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1055 - I1057
  • [17] Symptomatic Improvement Observed Within 2 Days of Etrasimod Induction Therapy: Results From ELEVATE UC 52 and ELEVATE UC 12 Studies in Patients With Ulcerative Colitis
    Dubinsky, Marla C.
    Vermeire, Severine
    Chaparro, Maria
    Irving, Peter M.
    Bartolome, Lauren
    Woolcott, John C.
    Rabbat, Christopher J.
    Wang, Wenjin
    Goetsch, Martina
    Torres, Joana
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S623 - S623
  • [18] HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH ETRASIMOD IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
    Armuzzi, Alessandro
    Rubin, David T.
    Schreiber, Stefan
    Panes, Julian
    Fellmann, Marc
    Bartolome, Lauren
    Goetsch, Martina
    Bhattacharjee, Abhishek
    Wu, Joseph
    Chaparro, Maria
    Dubinsky, Marla C.
    GASTROENTEROLOGY, 2023, 164 (06) : S689 - S689
  • [19] Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
    Armuzzi, A.
    Rubin, D. T.
    Schreiber, S.
    Panes, J.
    Fellmann, M.
    Bartolome, L.
    Goetsch, M.
    Bhattacharjee, A.
    Wu, J.
    Chaparro, M.
    Dubinsky, M. C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 593 - 594
  • [20] MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
    Sands, Bruce E.
    Vermeire, Severine
    Dubinsky, Marla C.
    Feagan, Brian G.
    Panaccione, Remo
    Jairath, Vipul
    Yarur, Andres J.
    Chiorean, Michael V.
    Panes, Julian
    Goetsch, Martina
    Rabbat, Christopher J.
    Shah, Pooja
    Wu, Joseph
    Ghosh, Subrata
    GASTROENTEROLOGY, 2023, 164 (06) : S1084 - S1085
12345